TTD | Drug: D02IWC

Drug General Information
Drug ID	D02IWC
Former ID	DCL000464
Drug Name	AZD2624
Drug Type	Small molecular drug
Indication	Schizophrenia [ICD9: 295; ICD10:F20]		Discontinued in Phase 2	[522334], [541098]
Company	AstraZeneca
Structure		Download 2D MOL
Formula	C26H25N3O3S
InChI	InChI=1S/C26H25N3O3S/c1-3-21(18-12-6-4-7-13-18)28-26(30)23-20-16-10-11-17-22(20)27-24(19-14-8-5-9-15-19)25(23)29-33(2,31)32/h4-17,21,29H,3H2,1-2H3,(H,28,30)/t21-/m0/s1
InChIKey	QYTBBBAHNIWFOD-NRFANRHFSA-N
PubChem Compound ID	23649245
PubChem Substance ID	46520831, 56028527, 137895626, 172113554, 178102400, 198974890, 224156816, 229591064, 243562193, 251962985
Target and Pathway
Target(s)	Nigral tachykinin NK(3) receptor	Target Info	Modulator
KEGG Pathway	Calcium signaling pathway
KEGG Pathway	Neuroactive ligand-receptor interaction
Reactome	G alpha (q) signalling events
WikiPathways	Gastrin-CREB signalling pathway via PKC and MAPK
	Peptide GPCRs
	GPCR ligand binding
	GPCR downstream signaling
References
Ref 522334	ClinicalTrials.gov (NCT00686998) Phase IIA Study in Patients With Schizophrenia. U.S. National Institutes of Health.
Ref 541098	(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5775).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.

Drug Information